11 completed, 2 terminated, 1 withdrawn. 9 Phase 3, 2 Not applicable, 2 Phase 4, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 9 | Completed 9 |
| Not applicable | 2 | Completed 1, Terminated 1 |
| Phase 4 | 2 | Terminated 1, Withdrawn 1 |
| Phase 2 | 1 | Completed 1 |
Follow Foradil: new trials by email Literature Review of Foradil trials Research Report on Foradil
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ANTES B+ Clinical Trial Trelegy Ellipta 100/62.5/25Mcg Inh 30D, Brimica, Duaklir - Chronic Obstructive Pulmonary Disease | Phase 4 | Terminated | Fundacio Privada Mon Clinic Barcelona | 48 | 2024-02-29 | 2025-08-14 |
| COPD Aerosol Study Comparing the Efficacy of Nebulizers Versus Dry Powder Inhalers Formoterol, Placebo - COPD Exacerbation | Not applicable | Completed | University of Tennessee Graduate School of Medicine | 7 | 2015-02-01 | 2019-03-19 |
| Blacks and Exacerbations on Long Acting Beta Agonists (LABA) vs. Tiotropium (BELT) Tiotropium, Salmeterol, Formoterol - Asthma | Phase 3 | Completed | Brigham and Women's Hospital | 1070 | 2011-03-30 | 2018-03-30 |
| Effect of Gly16Arg Polymorphism in ADRB2 Gene on Asthma Control in Children Receiving Long Acting Beta Agonists open-labeled inhaled corticosteroids (ICS); FORADIL® AEROLIZER®, foradil placebo, foradil - Safety of Long Acting Beta Agnoists | Phase 4 | Withdrawn | Nemours Children's Clinic | 2010-10-01 | 2023-05-26 | |
| Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease BI 1744, bi1744, Placebo - Pulmonary Disease, Chronic Obstructive | Phase 3 | Completed | Boehringer Ingelheim | 99 | 2009-06-01 | 2014-07-01 |
| Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease BI 1744 (Olodaterol) Low Dose, BI 1744 (Olodaterol) Medium Dose, Placebo - Pulmonary Disease, Chronic Obstructive | Phase 3 | Completed | Boehringer Ingelheim | 100 | 2009-06-01 | 2016-02-05 |
| The Effects of Different Long-acting Bronchodilator Medications on Asthma Patients With Different Genetic Variations tiotropium bromide, Salmeterol, Formoterol - Asthma | Not applicable | Terminated | Brigham and Women's Hospital | 255 | 2008-06-01 | 2017-05-31 |
| Effects of Mometasone Furoate/Formoterol Combination Versus Formoterol and Mometasone Furoate Alone in COPD (Study P04229AM4)(COMPLETED) Mometasone furoate/formoterol (MF/F) combination, Mometasone furoate MDI (MF MDI), Formoterol MDI - Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | Completed | Organon and Co | 1055 | 2006-10-01 | 2024-05-20 |
| Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04334AM1)(COMPLETED) mometasone furoate/formoterol fumarate combination MDI 200/10 mcg BID, Mometasone furoate MDI (MF MDI) 200 mcg, formoterol fumarate 10 mcg - Asthma | Phase 3 | Completed | Organon and Co | 781 | 2006-09-01 | 2024-05-20 |
| Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04073AM1)(COMPLETED) Mometasone Furoate/Formoterol Fumarate Combination MDI 100/10 mcg BID, Mometasone Furoate MDI (MF MDI), Formoterol Fumarate 10 mcg - Asthma | Phase 3 | Completed | Organon and Co | 746 | 2006-09-01 | 2024-05-17 |
| Effects of Mometasone Furoate/Formoterol Combination Versus Formoterol and Mometasone Furoate Alone in Chronic Obstructive Pulmonary Disease (COPD) (Study P04230AM4)(COMPLETED) Mometasone furoate/formoterol (MF/F) combination, Mometasone furoate MDI (MF MDI), Formoterol MDI - Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | Completed | Organon and Co | 1196 | 2006-09-01 | 2024-05-23 |
| Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease Arformoterol tartrate inhalation solution, Arformoterol 25 ųg BID, Formoterol 12 ųg BID - Chronic Obstructive Pulmonary Disease, Bronchitis | Phase 3 | Completed | Sumitomo Pharma America, Inc. | 443 | 2005-10-01 | 2012-06-04 |
| Formoterol-HFA 3-month Study in Chronic Obstructive Pulmonary Disease (COPD) Patients Formoterol - Chronic Obstructive Pulmonary Disease | Phase 3 | Completed | Chiesi Farmaceutici S.p.A. | 457 | 2005-08-01 | 2011-12-13 |
| Formoterol Via pMDI HFA-134a Propellant or DPI in Partially Reversible Chronic Obstructive Pulmonary Disease (COPD) Formoterol, Placebo - Chronic Obstructive Pulmonary Disease | Phase 2 | Completed | Chiesi Farmaceutici S.p.A. | 54 | 2004-09-01 | 2020-07-31 |
Pulmonary Disease, Chronic Obstructive (9) · Asthma (4) · Bronchitis (1) · Bronchitis, Chronic (1) · Emphysema (1)
Organon and Co (4) · Boehringer Ingelheim (2) · Brigham and Women's Hospital (2) · Chiesi Farmaceutici S.p.A. (2) · Fundacio Privada Mon Clinic Barcelona (1) · Nemours Children's Clinic (1) · Sumitomo Pharma America, Inc. (1) · University of Tennessee Graduate School of Medicine (1)
United States (6) · Italy (1) · Poland (1) · Spain (1)
Elliot Israel, MD (2) · Carlo Mereu, MD (1) · Gennaro D'Amato, MD (1) · Giorgio Canonica, MD (1) · Giorgio Scano, MD (1) · Giovanni Barisione, MD (1) · Iwona Graelewska Rzymowska, Prof (1) · Leonardo Fabbri, MD (1) · Pierluigi Paggiaro, MD (1) · Rajiv Dhand, MD (1) · Roberto Dal Negro, MD (1) · Vito Brusasco, MD, PhD (1)
PMID 22334770, PMID 25044280, PMID 25187881, PMID 20678306, PMID 21689019, PMID 21828036, PMID 22334768, PMID 22334769, PMID 26505596, PMID 36472162
2023 (1)